BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 17, 2006
View Archived Issues
Neurocrine Shares Dumped As FDA Sets Back Indiplon
The FDA delayed approving an immediate-release version of the sleep drug indiplon and rejected a modified-release formulation, actions that on Tuesday crushed the stock of Neurocrine Biosciences Inc. (BioWorld Today)
Read More
Intercept Brings In $41M To Target FXR In Liver Disease
Read More
Dyax Plunges On Warning Of More Work With DX-88
Read More
Viron Raises $25M In Series A For Viral Protein Therapeutics
Read More
Clinic Roundup
Read More
Other News To Note
Read More